Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
Optimi Health Corp. (OTCQX: OPTHF), a Canadian manufacturer of MDMA and naturally-derived psilocybin, has publicly filed a registration statement with the SEC for a proposed U.S. IPO. The company has applied to list its common shares on the Nasdaq Capital Market under the symbol "OPTH".
While the specific number of shares and price range are yet to be determined, Titan Partners Group will serve as the sole book-running manager for the offering. The registration statement (File Number: 333-290086) has been filed but is not yet effective, and securities cannot be sold until it becomes effective.
Optimi Health Corp. (OTCQX: OPTHF), società canadese che produce MDMA e psilocibina di origine naturale, ha depositato pubblicamente una dichiarazione di registrazione presso la SEC per una proposta IPO negli Stati Uniti. L'azienda ha fatto richiesta per quotare le proprie azioni ordinarie sul Nasdaq Capital Market con il simbolo "OPTH".
Il numero di azioni e la forchetta di prezzo non sono ancora stati determinati; Titan Partners Group agirà come unico gestore principale dell'offerta. La dichiarazione di registrazione (File Number: 333-290086) è stata presentata ma non è ancora efficace: i titoli non possono essere venduti fino al suo perfezionamento.
Optimi Health Corp. (OTCQX: OPTHF), una compañía canadiense que fabrica MDMA y psilocibina de origen natural, ha presentado públicamente una declaración de registro ante la SEC para una propuesta de IPO en EE. UU.. La empresa ha solicitado cotizar sus acciones ordinarias en el Nasdaq Capital Market bajo el símbolo "OPTH".
Aún no se han determinado el número de acciones ni el rango de precios; Titan Partners Group actuará como único administrador principal de la oferta. La declaración de registro (File Number: 333-290086) ha sido presentada pero no está en vigor, y los valores no pueden venderse hasta que lo esté.
Optimi Health Corp. (OTCQX: OPTHF)는 MDMA와 천연 유래 실로사이빈을 제조하는 캐나다 기업으로, 미국 IPO 추진을 위한 SEC 등록서류를 공개 제출했습니다. 회사는 자사 보통주를 나스닥 캐피탈 마켓(Nasdaq Capital Market)에 "OPTH"라는 심볼로 상장 신청했습니다.
발행 주식 수와 가격 범위는 아직 결정되지 않았으며, Titan Partners Group이 단독 주관사(북러닝 매니저)로 참여합니다. 등록서류(File Number: 333-290086)는 제출되었으나 아직 효력이 발생하지 않았고, 효력 발생 전에는 증권을 판매할 수 없습니다.
Optimi Health Corp. (OTCQX: OPTHF), un fabricant canadien de MDMA et de psilocybine d'origine naturelle, a déposé publiquement une déclaration d'enregistrement auprès de la SEC en vue d'une introduction en bourse proposée aux États-Unis. La société a demandé la cotation de ses actions ordinaires sur le Nasdaq Capital Market sous le symbole "OPTH".
Le nombre d'actions et la fourchette de prix n'ont pas encore été déterminés ; Titan Partners Group servira de gestionnaire principal unique pour l'offre. La déclaration d'enregistrement (File Number: 333-290086) a été déposée mais n'est pas encore effective : les titres ne peuvent pas être vendus tant qu'elle ne l'est pas.
Optimi Health Corp. (OTCQX: OPTHF), ein kanadischer Hersteller von MDMA und natürlich gewonnenen Psilocybin, hat eine Registrierungsunterlage bei der SEC für einen geplanten Börsengang in den USA öffentlich eingereicht. Das Unternehmen hat die Notierung seiner Stammaktien am Nasdaq Capital Market unter dem Symbol "OPTH" beantragt.
Die genaue Anzahl der Aktien und die Preisspanne stehen noch nicht fest; Titan Partners Group wird als alleiniger Book-Running-Manager der Platzierung fungieren. Die Registrierungsunterlage (File Number: 333-290086) wurde eingereicht, ist jedoch noch nicht wirksam — Wertpapiere dürfen erst nach Wirksamwerden verkauft werden.
- Potential access to larger U.S. capital markets through Nasdaq listing
- Enhanced visibility and trading liquidity for investors
- Strategic positioning in the growing psychedelics sector
- Uncertain offering terms and timeline
- No guarantee of successful listing completion
- Potential dilution for existing shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States.
The number of common shares to be sold and the price range for the proposed offering have not yet been determined. The Company has filed an application to list its common shares on the Nasdaq Capital Market under the symbol "OPTH." The filing of the application does not guarantee the listing of the Company's common shares, and the Company may withdraw its application due to future circumstances, market conditions or other factors.
Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the proposed offering.
The offering will be made only by means of a prospectus forming a part of the registration statement. Copies of the preliminary prospectus relating to the proposed offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 1000, by phone at (929) 833-1246 or by email to prospectus@titanpartnersgrp.com.
A registration statement on Form F-1 (File Number: 333-290086) relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. The proposed offering is subject to market and other conditions and the completion of the SEC's review process. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/265486_68afa3e1e4f9ca38_001full.jpg
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.ca. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265486
FAQ
When will Optimi Health (OPTHF) begin trading on the Nasdaq?
What is the IPO price range for Optimi Health's Nasdaq listing?
Who is managing Optimi Health's U.S. IPO?
What products does Optimi Health (OPTHF) manufacture?
What will be Optimi Health's new Nasdaq stock symbol?
